Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights

Non-dilutive funding to support development of first-in-concept lead Antibody-Drug Conjugate asset, PYX-201 Pyxis Oncology retains rights to three other antibodies in development by Apexigen’s...

Related Keywords

Boston ,Massachusetts ,United States ,Laras Sullivan ,Pamela Connealy ,Apexigen Inc ,Nasdaq ,Company Annual Report On Form ,Linkedin ,Pyxis Oncology Inc ,Twitter ,Novartis ,Exchange Commission ,Antibody Drug Conjugate ,Pyxis Oncology ,Private Securities Litigation Reform Act ,Annual Report ,Markets ,